Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Human Embryonic Stem Cell-Derived Cardiomyocytes Regenerate the Infarcted Pig Heart but Induce Ventricular Tachyarrhythmias.

Romagnuolo R, Masoudpour H, Porta-Sánchez A, Qiang B, Barry J, Laskary A, Qi X, Massé S, Magtibay K, Kawajiri H, Wu J, Valdman Sadikov T, Rothberg J, Panchalingam KM, Titus E, Li RK, Zandstra PW, Wright GA, Nanthakumar K, Ghugre NR, Keller G, Laflamme MA.

Stem Cell Reports. 2019 May 14;12(5):967-981. doi: 10.1016/j.stemcr.2019.04.005. Epub 2019 May 2.

2.

Training heart tissue to mature.

Dhahri W, Romagnuolo R, Laflamme MA.

Nat Biomed Eng. 2018 Jun;2(6):351-352. doi: 10.1038/s41551-018-0253-7. No abstract available.

PMID:
31011196
3.

Development of a Contractile Cardiac Fiber From Pluripotent Stem Cell Derived Cardiomyocytes.

Hansen KJ, Laflamme MA, Gaudette GR.

Front Cardiovasc Med. 2018 Jun 11;5:52. doi: 10.3389/fcvm.2018.00052. eCollection 2018.

4.

Cardiac repair with pluripotent stem cell-derived cardiomyocytes: Proof of concept but new challenges.

Masoudpour H, Laflamme MA.

J Thorac Cardiovasc Surg. 2017 Sep;154(3):945-948. doi: 10.1016/j.jtcvs.2017.05.088. Epub 2017 Jun 3. No abstract available.

PMID:
28688708
5.

Micro- and nano-patterned conductive graphene-PEG hybrid scaffolds for cardiac tissue engineering.

Smith AST, Yoo H, Yi H, Ahn EH, Lee JH, Shao G, Nagornyak E, Laflamme MA, Murry CE, Kim DH.

Chem Commun (Camb). 2017 Jun 29;53(53):7412-7415. doi: 10.1039/c7cc01988b.

6.

Programming cells for cardiac repair.

Romagnuolo R, Laflamme MA.

Curr Opin Biotechnol. 2017 Oct;47:43-50. doi: 10.1016/j.copbio.2017.05.011. Epub 2017 Jun 17. Review.

PMID:
28633074
7.

Optical Method to Quantify Mechanical Contraction and Calcium Transients of Human Pluripotent Stem Cell-Derived Cardiomyocytes.

Hansen KJ, Favreau JT, Gershlak JR, Laflamme MA, Albrecht DR, Gaudette GR.

Tissue Eng Part C Methods. 2017 Aug;23(8):445-454. doi: 10.1089/ten.TEC.2017.0190. Epub 2017 Jun 27.

8.

Mitochondrial Maturation in Human Pluripotent Stem Cell Derived Cardiomyocytes.

Dai DF, Danoviz ME, Wiczer B, Laflamme MA, Tian R.

Stem Cells Int. 2017;2017:5153625. doi: 10.1155/2017/5153625. Epub 2017 Feb 27.

9.

Human iPSC-derived cardiomyocytes and tissue engineering strategies for disease modeling and drug screening.

Smith AS, Macadangdang J, Leung W, Laflamme MA, Kim DH.

Biotechnol Adv. 2017 Jan - Feb;35(1):77-94. doi: 10.1016/j.biotechadv.2016.12.002. Epub 2016 Dec 20. Review.

10.

HLA Class I Depleted hESC as a Source of Hypoimmunogenic Cells for Tissue Engineering Applications.

Karabekian Z, Ding H, Stybayeva G, Ivanova I, Muselimyan N, Haque A, Toma I, Posnack NG, Revzin A, Leitenberg D, Laflamme MA, Sarvazyan N.

Tissue Eng Part A. 2015 Oct;21(19-20):2559-71. doi: 10.1089/ten.TEA.2015.0105. Epub 2015 Sep 10.

11.

Human pluripotent stem cells: Prospects and challenges as a source of cardiomyocytes for in vitro modeling and cell-based cardiac repair.

Hartman ME, Dai DF, Laflamme MA.

Adv Drug Deliv Rev. 2016 Jan 15;96:3-17. doi: 10.1016/j.addr.2015.05.004. Epub 2015 May 14. Review.

12.

Let-7 family of microRNA is required for maturation and adult-like metabolism in stem cell-derived cardiomyocytes.

Kuppusamy KT, Jones DC, Sperber H, Madan A, Fischer KA, Rodriguez ML, Pabon L, Zhu WZ, Tulloch NL, Yang X, Sniadecki NJ, Laflamme MA, Ruzzo WL, Murry CE, Ruohola-Baker H.

Proc Natl Acad Sci U S A. 2015 May 26;112(21):E2785-94. doi: 10.1073/pnas.1424042112. Epub 2015 May 11.

13.

Ribonucleotide reductase-mediated increase in dATP improves cardiac performance via myosin activation in a large animal model of heart failure.

Kadota S, Carey J, Reinecke H, Leggett J, Teichman S, Laflamme MA, Murry CE, Regnier M, Mahairas GG.

Eur J Heart Fail. 2015 Aug;17(8):772-81. doi: 10.1002/ejhf.270. Epub 2015 Apr 15.

14.

Exposure to phthalates affects calcium handling and intercellular connectivity of human stem cell-derived cardiomyocytes.

Posnack NG, Idrees R, Ding H, Jaimes R 3rd, Stybayeva G, Karabekian Z, Laflamme MA, Sarvazyan N.

PLoS One. 2015 Mar 23;10(3):e0121927. doi: 10.1371/journal.pone.0121927. eCollection 2015.

15.

Letter by Murry et al regarding article, "Embryonic stem cell-derived cardiac myocytes are not ready for human trials".

Murry CE, Chong JJ, Laflamme MA.

Circ Res. 2014 Oct 24;115(10):e28-9. doi: 10.1161/CIRCRESAHA.114.305042. No abstract available.

16.

Targeting survival pathways to create infarct-spanning bridges of human embryonic stem cell-derived cardiomyocytes.

Luo J, Weaver MS, Dennis JE, Whalen E, Laflamme MA, Allen MD.

J Thorac Cardiovasc Surg. 2014 Dec;148(6):3180-8.e1. doi: 10.1016/j.jtcvs.2014.06.087. Epub 2014 Jul 24.

17.

Methods for assessing the electromechanical integration of human pluripotent stem cell-derived cardiomyocyte grafts.

Zhu WZ, Filice D, Palpant NJ, Laflamme MA.

Methods Mol Biol. 2014;1181:229-47. doi: 10.1007/978-1-4939-1047-2_20.

18.

Pluripotent stem cell derived cardiomyocytes for cardiac repair.

Lundy SD, Gantz JA, Pagan CM, Filice D, Laflamme MA.

Curr Treat Options Cardiovasc Med. 2014 Jul;16(7):319. doi: 10.1007/s11936-014-0319-0.

19.

Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies.

Wang G, McCain ML, Yang L, He A, Pasqualini FS, Agarwal A, Yuan H, Jiang D, Zhang D, Zangi L, Geva J, Roberts AE, Ma Q, Ding J, Chen J, Wang DZ, Li K, Wang J, Wanders RJ, Kulik W, Vaz FM, Laflamme MA, Murry CE, Chien KR, Kelley RI, Church GM, Parker KK, Pu WT.

Nat Med. 2014 Jun;20(6):616-23. doi: 10.1038/nm.3545. Epub 2014 May 11.

20.

Cell-based delivery of dATP via gap junctions enhances cardiac contractility.

Lundy SD, Murphy SA, Dupras SK, Dai J, Murry CE, Laflamme MA, Regnier M.

J Mol Cell Cardiol. 2014 Jul;72:350-9. doi: 10.1016/j.yjmcc.2014.04.010. Epub 2014 Apr 26.

21.

Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts.

Chong JJ, Yang X, Don CW, Minami E, Liu YW, Weyers JJ, Mahoney WM, Van Biber B, Cook SM, Palpant NJ, Gantz JA, Fugate JA, Muskheli V, Gough GM, Vogel KW, Astley CA, Hotchkiss CE, Baldessari A, Pabon L, Reinecke H, Gill EA, Nelson V, Kiem HP, Laflamme MA, Murry CE.

Nature. 2014 Jun 12;510(7504):273-7. doi: 10.1038/nature13233. Epub 2014 Apr 30.

22.

Cobalt protoporphyrin pretreatment protects human embryonic stem cell-derived cardiomyocytes from hypoxia/reoxygenation injury in vitro and increases graft size and vascularization in vivo.

Luo J, Weaver MS, Cao B, Dennis JE, Van Biber B, Laflamme MA, Allen MD.

Stem Cells Transl Med. 2014 Jun;3(6):734-44. doi: 10.5966/sctm.2013-0189. Epub 2014 Apr 15.

23.

Myocardial deletion of transcription factor CHF1/Hey2 results in altered myocyte action potential and mild conduction system expansion but does not alter conduction system function or promote spontaneous arrhythmias.

Hartman ME, Liu Y, Zhu WZ, Chien WM, Weldy CS, Fishman GI, Laflamme MA, Chin MT.

FASEB J. 2014 Jul;28(7):3007-15. doi: 10.1096/fj.14-251728. Epub 2014 Mar 31.

24.

Electrical Integration of Human Embryonic Stem Cell-Derived Cardiomyocytes in a Guinea Pig Chronic Infarct Model.

Shiba Y, Filice D, Fernandes S, Minami E, Dupras SK, Biber BV, Trinh P, Hirota Y, Gold JD, Viswanathan M, Laflamme MA.

J Cardiovasc Pharmacol Ther. 2014 Jul;19(4):368-381. Epub 2014 Feb 10.

25.

Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes.

Nunes SS, Miklas JW, Liu J, Aschar-Sobbi R, Xiao Y, Zhang B, Jiang J, Massé S, Gagliardi M, Hsieh A, Thavandiran N, Laflamme MA, Nanthakumar K, Gross GJ, Backx PH, Keller G, Radisic M.

Nat Methods. 2013 Aug;10(8):781-7. doi: 10.1038/nmeth.2524. Epub 2013 Jun 23.

26.

Human embryonic stem cell-derived cardiomyocytes migrate in response to gradients of fibronectin and Wnt5a.

Moyes KW, Sip CG, Obenza W, Yang E, Horst C, Welikson RE, Hauschka SD, Folch A, Laflamme MA.

Stem Cells Dev. 2013 Aug 15;22(16):2315-25. doi: 10.1089/scd.2012.0586. Epub 2013 May 8.

27.

Structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells.

Lundy SD, Zhu WZ, Regnier M, Laflamme MA.

Stem Cells Dev. 2013 Jul 15;22(14):1991-2002. doi: 10.1089/scd.2012.0490. Epub 2013 Apr 5.

28.

Targeted genomic integration of a selectable floxed dual fluorescence reporter in human embryonic stem cells.

Gantz JA, Palpant NJ, Welikson RE, Hauschka SD, Murry CE, Laflamme MA.

PLoS One. 2012;7(10):e46971. doi: 10.1371/journal.pone.0046971. Epub 2012 Oct 10.

29.

Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts.

Shiba Y, Fernandes S, Zhu WZ, Filice D, Muskheli V, Kim J, Palpant NJ, Gantz J, Moyes KW, Reinecke H, Van Biber B, Dardas T, Mignone JL, Izawa A, Hanna R, Viswanathan M, Gold JD, Kotlikoff MI, Sarvazyan N, Kay MW, Murry CE, Laflamme MA.

Nature. 2012 Sep 13;489(7415):322-5. doi: 10.1038/nature11317.

30.

Aortic dissection in osteogenesis imperfecta: case report and review of the literature.

McNeeley MF, Dontchos BN, Laflamme MA, Hubka M, Sadro CT.

Emerg Radiol. 2012 Dec;19(6):553-6. doi: 10.1007/s10140-012-1044-1. Epub 2012 Apr 20. Review. No abstract available.

PMID:
22527359
31.

Human embryonic stem cells differentiated to lung lineage-specific cells ameliorate pulmonary fibrosis in a xenograft transplant mouse model.

Banerjee ER, Laflamme MA, Papayannopoulou T, Kahn M, Murry CE, Henderson WR Jr.

PLoS One. 2012;7(3):e33165. doi: 10.1371/journal.pone.0033165. Epub 2012 Mar 28.

32.

Methods for the derivation and use of cardiomyocytes from human pluripotent stem cells.

Zhu WZ, Van Biber B, Laflamme MA.

Methods Mol Biol. 2011;767:419-31. doi: 10.1007/978-1-61779-201-4_31.

33.

Heart regeneration.

Laflamme MA, Murry CE.

Nature. 2011 May 19;473(7347):326-35. doi: 10.1038/nature10147. Review.

34.

Efficient generation and cryopreservation of cardiomyocytes derived from human embryonic stem cells.

Xu C, Police S, Hassanipour M, Li Y, Chen Y, Priest C, O'Sullivan C, Laflamme MA, Zhu WZ, Van Biber B, Hegerova L, Yang J, Delavan-Boorsma K, Davies A, Lebkowski J, Gold JD.

Regen Med. 2011 Jan;6(1):53-66. doi: 10.2217/rme.10.91.

35.

Human embryonic stem cell-derived cardiomyocytes engraft but do not alter cardiac remodeling after chronic infarction in rats.

Fernandes S, Naumova AV, Zhu WZ, Laflamme MA, Gold J, Murry CE.

J Mol Cell Cardiol. 2010 Dec;49(6):941-9. doi: 10.1016/j.yjmcc.2010.09.008. Epub 2010 Sep 18.

36.

Proangiogenic scaffolds as functional templates for cardiac tissue engineering.

Madden LR, Mortisen DJ, Sussman EM, Dupras SK, Fugate JA, Cuy JL, Hauch KD, Laflamme MA, Murry CE, Ratner BD.

Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15211-6. doi: 10.1073/pnas.1006442107. Epub 2010 Aug 9.

37.

Neuregulin/ErbB signaling regulates cardiac subtype specification in differentiating human embryonic stem cells.

Zhu WZ, Xie Y, Moyes KW, Gold JD, Askari B, Laflamme MA.

Circ Res. 2010 Sep 17;107(6):776-86. doi: 10.1161/CIRCRESAHA.110.223917. Epub 2010 Jul 29.

38.

Differentiation of cardiomyocytes from human embryonic stem cells is accompanied by changes in the extracellular matrix production of versican and hyaluronan.

Chan CK, Rolle MW, Potter-Perigo S, Braun KR, Van Biber BP, Laflamme MA, Murry CE, Wight TN.

J Cell Biochem. 2010 Oct 15;111(3):585-96. doi: 10.1002/jcb.22744.

39.

Cardiac applications for human pluripotent stem cells.

Shiba Y, Hauch KD, Laflamme MA.

Curr Pharm Des. 2009;15(24):2791-806. Review.

40.

Local control of excitation-contraction coupling in human embryonic stem cell-derived cardiomyocytes.

Zhu WZ, Santana LF, Laflamme MA.

PLoS One. 2009;4(4):e5407. doi: 10.1371/journal.pone.0005407. Epub 2009 Apr 30.

41.

Cardiogenic differentiation and transdifferentiation of progenitor cells.

Reinecke H, Minami E, Zhu WZ, Laflamme MA.

Circ Res. 2008 Nov 7;103(10):1058-71. doi: 10.1161/CIRCRESAHA.108.180588. Review.

42.

Human embryonic stem cells and cardiac repair.

Zhu WZ, Hauch KD, Xu C, Laflamme MA.

Transplant Rev (Orlando). 2009 Jan;23(1):53-68. doi: 10.1016/j.trre.2008.05.005. Epub 2008 Jul 26. Review.

43.

Cell-based therapy for myocardial ischemia and infarction: pathophysiological mechanisms.

Laflamme MA, Zbinden S, Epstein SE, Murry CE.

Annu Rev Pathol. 2007;2:307-39. Review.

PMID:
18039102
44.

Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts.

Laflamme MA, Chen KY, Naumova AV, Muskheli V, Fugate JA, Dupras SK, Reinecke H, Xu C, Hassanipour M, Police S, O'Sullivan C, Collins L, Chen Y, Minami E, Gill EA, Ueno S, Yuan C, Gold J, Murry CE.

Nat Biotechnol. 2007 Sep;25(9):1015-24. Epub 2007 Aug 26.

PMID:
17721512
45.

Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response.

Nussbaum J, Minami E, Laflamme MA, Virag JA, Ware CB, Masino A, Muskheli V, Pabon L, Reinecke H, Murry CE.

FASEB J. 2007 May;21(7):1345-57. Epub 2007 Feb 6.

PMID:
17284483
46.

Confirmation of Chagas' cardiomyopathy following heart transplantation.

Phan BA, Laflamme MA, Stempien-Otero A, Limaye AP, Buckner FS, Levy WC.

Heart Vessels. 2006 Sep;21(5):325-7. Epub 2006 Sep 29.

PMID:
17151822
47.

Extracardiac progenitor cells repopulate most major cell types in the transplanted human heart.

Minami E, Laflamme MA, Saffitz JE, Murry CE.

Circulation. 2005 Nov 8;112(19):2951-8.

PMID:
16275883
48.

Proliferation of cardiomyocytes derived from human embryonic stem cells is mediated via the IGF/PI 3-kinase/Akt signaling pathway.

McDevitt TC, Laflamme MA, Murry CE.

J Mol Cell Cardiol. 2005 Dec;39(6):865-73. Epub 2005 Oct 19.

49.

Formation of human myocardium in the rat heart from human embryonic stem cells.

Laflamme MA, Gold J, Xu C, Hassanipour M, Rosler E, Police S, Muskheli V, Murry CE.

Am J Pathol. 2005 Sep;167(3):663-71.

50.

Regenerating the heart.

Laflamme MA, Murry CE.

Nat Biotechnol. 2005 Jul;23(7):845-56. Review.

PMID:
16003373

Supplemental Content

Loading ...
Support Center